Inebilizumab

CHEMBL2109334 Phase 4 Approuvé Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This humanized monoclonal antibody targets CD19, a protein found on B-cells, and depletes these immune cells to reduce the autoimmune attacks in neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, severe inflammatory disease affecting the optic nerves and spinal cord. By reducing B-cell numbers, it decreases the frequency of disabling attacks.

Aires thérapeutiques

Immunology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This humanized monoclonal antibody targets CD19, a protein found on B-cells, and depletes these immune cells to reduce the autoimmune attacks in neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, severe inflammatory disease affecting the optic nerves and spinal cord. By reducing B-cell numbers, it decreases the frequency of disabling attacks.

Yes, Inebilizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109334. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Inebilizumab sur PillFYI

Données Clés

Synonymes: 1

Liens externes

ChEMBL CHEMBL2109334

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.